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The aim of the work was to study the impact of fetal rat brain cell supernatant (FRBCS) on the expression of transforming growth 
factor β1 (TGF-β1) and p53 in C6 cells of rat glioma in vitro. Materials and Methods: FRBCS was obtained from suspensions 
of fetal rat brain cells on the 14th (E14) day of gestation. C6 glioma cells were cultured for 48 h in the presence of FRBCS or FRBCS 
+ anti-TGF-β1 monoclonal antibody. Immunocytochemical staining for TGF-β1 and p53 was performed. Results: The proportion 
of TGF-β1-immunopositive tumor cells in C6 glioma cultures was statistically significantly higher than in the control cell cultures 
of normal fetal rat brain. FRBCS reduced the proportion of TGF-β1-immunopositive tumor cells and increased the proportion 
of p53-immunopositive cells in C6 glioma cultures. In cells cultured with FRBCS + anti-TGF-β1 monoclonal antibody, the above 
effects of FRBCS were abrogated. Conclusion: The obtained results suggest that TGF-β1 seems to be responsible for decrease 
in TGF-β1 expression and increase in p53 expression in C6 glioma cells treated with FRBCS.
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According to the National Cancer Registry, the 
incidence of malignant brain tumors in Ukraine 
in 2014 was 5.2 per 100,000 of population, and mor-
tality — 3.9 per 100,000 [1]. Among primary tumors 
of central nervous system, glial tumors predominate. 
The malignant glioblastomas are difficult to treat 
because of their invasiveness and high recurrence 
rate. In neurooncology, criteria for individualization 
of patient treatment are actively developed by iden-
tifying a unique set of molecular changes in cancer 
cells providing for personalized or targeted therapy. 
As targets for personalized therapy of brain tumors, 
the markers of proliferation, neuroepithelial stem cell 
markers, regulators of cell proliferation, differentia-
tion, survival and/or apoptosis are considered [2]. 
The use of neural stem and progenitor cells (NSC/
NPC) is one of the approaches for the treatment of gli-
omas [3–6]. The similarities between NSC and brain 
cancer stem cells (CSC) are being studied [7–13]. 
It is believed that NSC/NPC may be used to induce 
long-term antitumor response by stimulating the im-
mune system and for delivery of various biological 
agents to tumor [14, 15]. In the setting of experi-
mental glioblastomas, it is shown that the NPC can 
migrate to the tumor inducing tumor cell death [15]. 
The use of NPC prolongs the survival of animals 
or almost completely inhibits glioma growth [16], but 
the mechanism of NPC antitumor effects remains 
unclear.
The cultures of tumor cells are widely used for 
developing new approaches to the treatment of brain 
cancer [17]. In previous studies, we demonstrated 
cytotoxic and antimitotic effects of fetal rat brain cell 
supernatant (FRBCS) on 101.8 and C6 glioma cells 
in vitro [18, 19] with reduction of the number of Ki-
67-immunopositive cells [20] and CD133-positive 
cells in C6 glioma cell culture [21]. These proper-
ties seem to be mediated by soluble factors such 
as TGF-β produced by NSC/NPC [18, 22, 23].
TGF-β is known as an important mediator of the ma-
lignant phenotype of human brain gliomas [24] while 
TGF-β signaling is involved in the regulation of prolif-
eration, differentiation and survival/or apoptosis [25]. 
The antiproliferative effect of TGF-β1 on epithelial cells 
in the early stages and promoting effect in the later 
stages of tumor growth was shown [26]. It is believed 
that TGF-β1 signaling is a potential target for antitu-
mor therapy, while the expression of TGF-β increases 
significantly in gliomas with high degree of malignan-
cy [25, 27, 28]. Inhibitors of TGF-β1 signaling reduce 
viability and invasive properties of gliomas modeled 
in animals [25].
The study of the possible pro-apoptotic effects 
of FRBCS and the expression of well-known tumor 
suppressor protein p53 is no less important. P53 func-
tions as a transcription factor that regulates genes 
involved in the cellular response to stress; activation 
of p53 leads to the induction of DNA repair, cell cycle 
arrest and apoptosis, whereas loss of p53 responses 
due to mutations promotes uncontrolled cell prolifera-
tion [29].
The aim of the work was to study the impact 
of FRBCS on the expression of TGF-β1 and p53 in gli-
oma cells in vitro.
MATERIALS AND METHODS
Cell lines. Rat glioma cells C6 were obtained 
from the Bank of Cell Lines from Human and Animal 
Tissues, R.E. Kavetsky Institute of Experimental 
Submitted: November 18, 2016. 
*Correspondence:  E-mail: Lyubichld@gmail.com 
Abbreviations used: CSC — cancer stem cells; FRBCS — fetal rat 
brain cell supernatant; NPC — neural progenitor cells; NSC — neu-
ral stem cells; TGF-β1 — transforming growth factor β1. 
Exp Oncol 2017
39, 4, 258–263
ORIGINAL CONTRIBUTIONS
Experimental Oncology 39, 258–263, 2017 (December) 259
Pathology, Oncology and Radiobiology, the National 
Academy of Sciences, Kyiv). The cells of fetal rat brain 
(E14) were obtained under the protocol [21]. The vi-
ability of cells was determined in a standard test with 
0.2% trypan blue (Merck, Germany) [21]. 1•106 cells 
were applied onto the adhesive coverslips coated 
with polyethylenimine (Sigma, USA), which were 
placed in Petri dishes and cultured in DMEM medium 
(2 ml, Sigma, USA), supplemented with 1% fetal calf 
serum (Sigma, USA), glucose (400 mg%) and insulin 
(0.2 U/ml). Cells were cultured in a CO2-incubator 
(37 °С, 95% humidity and 5% CO2) and observed 
in inverted microscope (Eclips TS 100, Japan) with 
microphotographic registration.
FRBCS. Fetal rat brain cells removed on the 14th 
(E14) day of gestation were cultured as previously 
described [18] and supernatant (0.10 mg/ml) was col-
lected. Earlier we showed that 49–50% of E14 cells are 
nestin-immunopositive [30] and 37–40% — CD133-
immunopositive [21], i.e. these cells are positive for 
NSC markers.
Monoclonal antibodies. Monoclonal antibody 
to TGF-β1 (anti-transforming growth factor-β1, 
clone 9016.2; Sigma, USА) and rabbit antibody 
to р53 (anti-TP53 antibody; Sigma- Aldrich, USА) 
were used. For FRBCS neutralization, FRBCS 
(0.10 mg/ml) was mixed with monoclonal anti-
body to TGF-β1 (0.10 µg/ml) and incubated for 
20–30 min prior to addition to the experimental 
cultures.
Immunocytochemical staining for TGF-β1 and 
p53. Cells fixed on coverslips were rehydrated, incu-
bated in 0.1% solution of Triton X-100 (Sigma, USA) 
at room temperature for 30 min, and then washed 
three times for 5 min in 0.01 M phosphate buffer 
(рН 6.0). To block endogenous peroxidase, the cov-
erslips were incubated in the dark for 10 min with 3% 
H2O2 solution and then rinsed for 5 min in phosphate 
buffer. To block nonspecific background staining, 
coverslips were incubated 5 min with 1% solution 
of bovine serum albumin (Sigma, USА). Mouse 
monoclonal antibody to TGF-β1 or rabbit antibody 
to p53 were applied at a dilution of 1:100 for 60 min 
at room temperature. After triple washing in buffer, 
the secondary antibody (goat antimouse/antirab-
bit IgG peroxidase conjugated (Dako, Denmark) 
at a dilution of 1:200 were applied for 30 min at room 
temperature followed by treatment with diaminoben-
zidine solution (Dako, Denmark) for 2 min and the 
development of specific coloration was controlled 
under the microscope. After washing with distilled 
water, the cells were stained with hematoxylin and 
the specimens were embedded in balsam. Parallel 
studies were performed with positive and negative 
controls. The stained specimens were examined 
under AxioImager A2 microscope (Carl Zeiss Mi-
croscopy GmbH, Germany) with a broadband filter 
equipped with camera AxioCam MRc5 (Carl Zeiss 
Microscopy GmbH, Germany). TGF-β1- and p53-
immunopositive and negative cells were counted 
Fig. 1. Change in the TGF-β1 expression in C6 glioma cells treated with FRBCS. Immunocytochemical staining for TGF-β1 and coun-
terstaining with hematoxylin, × 2000, immersion: a — C6 cells, control; b — culture of fetal rat brain cells (E14), control; c — C6 cells 
incubated with FRBCS (E14), 0.10 mg/ml, 48 h; d — C6 cells incubated with a mixture of FRBCS (E14, 0.10 mg/ml) and antibody 
to TGF-β1 (0.10 mg/ml), 48 h
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in 10 representative fields of view with standard 
measurement scale (object-micrometer). Digital 
images analysis was performed using the software 
“Zen Lite 2012” (Germany).
Statistical analysis. Statistica 8.0, software 
StatSoft, Inc. (2007) was used for nonparametric 
Mann — Whitney U-test for comparison of indepen-
dent groups. Normality of data distribution was deter-
mined Shapiro — Wilkie test. A statistically significant 
difference was considered when p < 0.05, statistically 
highly significant — when p < 0.01.
RESULTS AND DISCUSSION
Immunostaining for TGF-β1 revealed 48.81 ± 7.91% 
of TGF-β1-immunopositive cells in control glioma 
C6 specimens (Fig. 1, a; Fig. 2) that exceeds signifi-
cantly the percentage of TGF-β1-immunopositive cells 
in, control cell cultures of normal fetal rat brain (E14) 
(22.04 ± 2.33%, Mann — Whitney U-test, p = 0.048; 
Fig. 1, b; Fig. 2).
After 48 h of incubation of C6 glioma cultures with 
FRBCS in a concentration of 0.10 mg/ml, the fraction 
of TGF-β1-immunopositive tumor cells statistically 
significantly decreased to 29.18 ± 7.24% (Mann — 
Whitney U-test, p = 0.0003 compared to control; 
Fig. 1, c; Fig. 2). The incubation of C6 cells with 
a mixture of FRBCS and monoclonal antibodies 
to TGF-β1 abrogated the decrease of TGF-β1-
immunopositive fraction in cultures treated with 
FRBCS as a single agent (p = 0.05, Mann — Whitney 
U-test; Fig. 1, d; Fig. 2). Earlier we reported that 
FRBCS contains TGF-β1 in an amount of 12.0 pg/
ml [18]. Therefore, the decrease of TGF-β1-
immunopositive cell count in glioma C6 culture 
after incubation with FRBCS may be presumably 
explained by the effects of TGF-β1 as the compo-
nent of FRBCS.
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Fig. 2. Quantitative indicators of changes in the expression 
of TGF-β1 in C6 glioma cells treated with FRBCS, 0.10 mg/ml, 
48 h: 1 — glioma C6 cells, control; 2 — glioma C6 cells incu-
bated with FRBCS (E14), 0.10 mg/ml, 48 h; 3 — glioma C6 cells 
incubated with a mixture of FRBCS (E14, 0.10 mg/ml) and 
antibody to TGF-β1 (0.10 mg/ml), 48 h; 4 — culture of fetal rat 
brain cells (E14), control. M — mean value; m — standard error 
of the mean; d — standard deviation from the mean
We also examined the expression of p53 in C6 gli-
oma cells treated with FRBCS. In control C6 cells 
the fraction of p53-immunopositive cells was 
8.94 ± 6.05% (Fig. 3, a; Fig. 4). After 48 h of incuba-
tion with FRBCS in a concentration of 0.10 mg/ml the 
fraction of p53-immunopositive C6 cells statistically 
significantly increased to 18.47 ± 10.62% (Mann — 
Whitney U-test, p = 0.01 compared to control; 
Fig. 3, b; Fig. 4). Again, this effect of FRBCS 
was сanceled when monoclonal  ant ibodies 
to TGF-β1 were added (p = 0.003 compared with 
cultures incubated only with FRBCS, Mann — Whit-
ney U-test; Fig. 3, c; Fig. 4). That is, while adding 
to the C6 glioma cells a mixture of FRBCS and 
monoclonal antibody to TGF-β1 the neutralization 
Fig. 3. Change of the p53 expression in C6 glioma cells treated 
with FRBCS. Immunocytochemical staining for p53 and coun-
terstaining with hematoxylin, × 2000, immersion: a — C6 cells, 
control; b — C6 cells incubated with FRBCS (E14), 0.10 mg/ml, 
48 h; c — C6 cells incubated with a mixture of FRBCS (E14, 
0.10 mg/ml) and antibody to TGF-β1 (0.10 mg/ml), 48 h
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of FRBCS effect took place because of binding 
molecules of TGF-β1 with specific monoclonal an-
tibodies. In our view, this indicates that the estab-
lished effect (increase of p53-immunopositive cells 
in glioma C6 cultures) after incubation with FRBCS 
takes place due to the influence of TGF-β1, which 
is a component of FRBCS.
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Fig. 4. Quantitative indicators of changes in the expression 
of p53 in C6 glioma cells treated with FRBCS, 0.10 mg/ml, 
48 h): 1 — glioma C6 cells, control; 2 — glioma C6 cells incubated 
with FRBCS (E14), 0.10 mg/ml, 48 h; 3 — glioma C6 cells incu-
bated with a mixture of FRBCS (E14, 0.10 mg/ml) and antibody 
to p53 (0.10 mg/ml), 48 h; M — mean value; m — standard error 
of the mean; d — standard deviation from the mean
So we have shown, firstly: two-fold increase 
of cells expressing TGF-β1, in C6 glioma cell cultures 
compared with cell cultures of normal fetal brain; 
secondly: reduction of TGF-β1-immunopositive 
cell number in C6 glioma cultures after FRBCS 
treatment. The obtained results are generally 
agreed with the known data about mutations of the 
components of TGF-β1-signaling pathways in cells 
of gliomas, as well as autocrine-paracrine mecha-
nism of TGF-β1, effects [24, 31].
In this regard it should be noted that under physi-
ological conditions TGF-β plays an important role 
in the embryo- and morphogenesis and in main-
tenance of tissue homeostasis [31, 32]. In par-
ticular, according to immunohistochemical studies 
of Pelton et al. [31], few TGF-β1-immunoreactive 
cells, and a significant number of TGF-β2-, TGF-β3-
immunoreactive cells were identified in embryonic 
tissue of the central nervous system of mouse in fe-
tuses aged 12.5–18.5 days. The authors concluded 
that the isoforms of the growth factor TGF-β during 
embryogenesis of mammals work by both paracrine 
and autocrine mechanism, regulate differentiation 
(by stimulation or inhibition, depending on the type 
of cells), stimulate the formation of extracellular 
matrix, act as chemoattractant for certain cells, 
and also induce mesoderm formation during early 
development [31]. Other researchers have shown 
that multipotent human, rat and mouse NPC are able 
to produce all isotypes of TGF-β, in particular, TGF-β1, 
TGF-β2, which may explain the immunosuppressive 
nature of these cells [22, 23].
In setting of pathology, TGF-β has a dual role. 
On the one hand, TGF-β is an important mediator 
of the malignant phenotype of human brain gliomas 
being involved in the regulation of proliferation, differ-
entiation and survival/or apoptosis [25], modulation 
of invasiveness, angiogenesis, evasion of immune 
control and maintenance of CSC in brain [24, 33–35]. 
On the other hand, TGF-β is a strong inhibitor of pro-
liferation of epithelial cells, astrocytes, immune cells 
and is considered as tumor-suppressive factor [24, 
36]. Other authors reported TGF-β1 antiprolifera-
tive effect of TGF-β1 in a number of epithelial cells 
in the early stages and promoter effect in the later 
stages of tumor growth [26, 32]. Tumor-suppressive 
function of TGF-β includes inhibition of proliferation, 
induction of apoptosis, regulation of autophagy, but 
with the development of tumors the response of cells 
to TGF-β shifts. As a result TGF-β acts as a potential 
promoter of cell motility, invasion, metastasis and 
CSC maintenance in brain [37]. In carcinogenesis, 
TGF-β SMAD-dependent signaling pathway cor-
relates with antiproliferative and tumor-suppressive 
functions of TGF-β, while SMAD-independent way 
is involved in pro-tumor functions of TGF-β [26, 32]. 
This occurs as a result of mutations of canonical TGF-
β-signaling pathway elements in malignant gliomas, 
which allow avoiding the antiproliferative influence 
of TGF-β, thereby contributing to its promoting 
activity [24]. TGF-β modulates the response of glio-
blastoma cells by autocrine way, all three isoforms 
of TGF-β are expressed being biologically active 
in glioblastoma cells [24]. The total result of this multi-
directional (antiproliferative or stimulating) effect 
of the TGF-β can vary between different specimens 
of tumors and even between different parts of the 
same tumor [24].
It is believed that TGF-β-signaling is a potential 
target for the therapy of cancer as the expression 
of TGF-β isoforms increases significantly in gliomas 
with high degree of malignancy [24, 25, 27, 28, 32, 
38], helping tumor to avoid immune recognition via 
various mechanisms, including inhibition of CD8+ cy-
totoxic lymphocytes and natural killer cells [39] and 
stimulation of the generation of T regulatory cells. 
The three levels of therapeutic strategy of TGF-β-
signaling inhibition are considered: the ligand itself, 
the ligand — receptor interactions and the intracel-
lular signaling cascade [32]. Inhibitors of TGF-β-
signaling, namely, neutralizing monoclonal antibodies 
to TGF-β used in combination with vaccine based 
on glioma-associated antigen peptides reduce viability 
and invasive properties of gliomas in animals [25] con-
tributing to lengthening the average life span mice with 
GL261 glioma [27]. The knockdown of TGF-β receptor 
type 2 reduced invasiveness of glioma CSC in vivo [40].
We have demonstrated that FRBCS reduced the 
proportion of TGF-β1-immunopositive C6 glioma 
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cells and increased the proportion of p53-immu-
nopositive cells. Nevertheless, a mixture of FRBCS 
and anti-TGF-β1 monoclonal antibody neutralized 
the above biological effects of FRBCS in C6 glioma 
cells. Thus, our data suggest that TGF-β1 seems 
to be responsible for decrease in TGF-β1 expression 
and increase in p53 expression in C6 glioma cells 
treated with FRBCS.
The obtained results, in our opinion, may become 
the basis for further research for the purpose of theo-
retical substantiation of complex pathogenetic therapy 
of the patients with gliomas including the use of the 
products derived from fetal neurogenic cells.
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